SULFADIAZINE AND SODIUM SULFADIAZINE: A COMPARISON OF CERTAIN OF THEIR CLINICAL AND PHARMACOLOGIC VALUES
Authors: Charles Wheeler, Norman Plummer
Journal: Annals of Internal Medicine (1942)

Article1 February 1942SULFADIAZINE AND SODIUM SULFADIAZINE: A COMPARISON OF CERTAIN OF THEIR CLINICAL AND PHARMACOLOGIC VALUESCHARLES WHEELER, M.D., NORMAN PLUMMER, M.D., F.A.C.P.CHARLES WHEELER, M.D.Search for more papers by this author, NORMAN PLUMMER, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-16-2-269 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSulfadiazine (2-sulfanilamido-pyrimidine) and sodium sulfadiazine are following sulfathiazole and sodium sulfathiazole in experimental and clinical trial just as these thiazole derivatives followed sulfapyridine and its sodium salt. Already a number of reports1-10 on the absorption, excretion, acetylation, diffusion, toxicity, and therapeutic effects of sulfadiazine in man have appeared, but because the indication is strong that sulfadiazine and its sodium salt will displace largely the other sulfonamide drugs, additional observations on the pharmacology of this drug seem important.Previous reports on the pharmacology of sulfadiazine have dealt primarily with the observations made following a single dose of the drug and in...Bibliography1. PLUMMERENSWORTH NHK: Absorption and excretion of sulfadiazine, Proc. Soc. Exper. Biol. and Med., 1940, xlv, 734. CrossrefGoogle Scholar2. REINHOLDFLIPPINSCHWARTZDOMM JGHFLAH: The absorption, distribution and excretion of 2-sulfanilamido pyrimidine (sulfapyrimidine, sulfadiazine) in man, Am. Jr. Med Sci., 1941, cci, 106. CrossrefGoogle Scholar3. PETERSONSTRAUSSTAYLORFINLAND OLSFHM: Absorption, excretion and distribution of sulfadiazine (2-Sulfanilamido pyrimidine), Am. Jr. Med. Sci., 1941, cci, 357. CrossrefGoogle Scholar4. SADUSKTREDWAY JFJB: Observations on the absorption, excretion, diffusion and acetylation of sulfadiazine in man, Yale Jr. Biol. and Med., 1941, xiii, 539. Google Scholar5. FLIPPINROSESCHWARTZDOMM HFSBLAH: Sulfadiazine and sulfathiazole in the treatment of pneumococcic pneumonia, Am. Jr. Med. Sci., 1941, ccci, 585. CrossrefGoogle Scholar6. PLUMMERLIEBMANSOLOMONKAMMERERKALKSTEINENSWORTH NJSWHMHK: Chemotherapy versus combined chemotherapy and serum in the treatment of pneumonia. A study of 607 alternated cases, Jr. Am. Med. Assoc., 1941, cxvi, 2366. CrossrefGoogle Scholar7. LONG PH: Sulfadiazine. The 2-sulfanilamido pyrimidine analogue of sulfanilamide, Jr. Am. Med. Assoc., 1941, cxvi, 2399. CrossrefGoogle Scholar8. FINLANDSTRAUSSPETERSON MEOL: Sulfadiazine. Therapeutic evaluation and toxic effects on 446 patients, Jr. Am. Med. Assoc., 1941, cxvi, 2641. CrossrefGoogle Scholar9. DINGLETHOMASMORTON JHLAR: Treatment of meningococcic meningitis and meningococcemia with sulfadiazine, Jr. Am. Med. Assoc., 1941, cxvi, 2666. CrossrefGoogle Scholar10. DOWLINGHARTMANSUGARFELDMAN HFCRSJHA: Treatment of pneumococcic pneumonia with sulfadiazine, Jr. Am. Med Assoc., 1941, cxvii, 824. CrossrefGoogle Scholar11. BRATTONMARSHALL ACEK: A new coupling component for sulfanilamide determination, Jr. Biol. Chem., 1939, cxxviii, 537. CrossrefGoogle Scholar12. CALLOMONGOODPASTOR VBWE: Sulfathiazole in the treatment of pneumococcus pneumonia, ANN. INT. MED., 1940, xiv, 1024. Google Scholar13. ABERNATHYDOWLINGHARTMAN TJHFCR: The treatment of lobar pneumonia with sulfapyridine and sodium sulfapyridine with observations upon effective blood levels, ANN. INT. MED., 1940, xiii, 1121. Google Scholar14. WINTERSRHOADSWAYNEROSI WLPSWFR: The treatment of pneumococcic pneumonia with sulfapyridine, ANN. INT. MED., 1941, xiv, 1827. Google Scholar15. REINHOLDFLIPPINSCHWARTZ JGHFL: Observations on the pharmacology and toxicology of sulfathiazole in man, Am. Jr. Med. Sci., 1940, cxcix, 393. CrossrefGoogle Scholar16. FLIPPINREINHOLDSCHWARTZ HFJGL: Sulfapyridine and sulfathiazole therapy in pneumococcic pneumonia, Jr. Am. Med. Assoc., 1941, cxvi, 683. CrossrefGoogle Scholar17. BARLOWCLIMENKO OWDR: Studies on the pharmacology of sulfapyridine and sulfathiazole, Jr. Am. Med. Assoc., 1941, cxvi, 282. CrossrefGoogle Scholar18. RATISHDAVIDSONBULLOWA HDAJG: Absorption and excretion of sulfapyridine and sodium sulfapyridine in man, Jr. Pharm. and Exper. Therap., 1940, lxix, 365. Google Scholar19. STRAUSSLOWELLTAYLORFINLAND EFCFHM: Observations on the absorption, excretion, and distribution of sulfanilamide, sulfapyridine, sulfathiazole, and sulfamethylthiazole, ANN. INT. MED., 1941, xiv, 1360. Google Scholar20. STOKINGER HE: Absorption, acetylation, and excretion of 2-sulfanilamid pyridine (Dagenan, M & B 693), Proc. Soc. Exper. Biol. and Med., 1939, xl, 61. CrossrefGoogle Scholar21. LONGFEINSTONE PHWH: Observations upon the absorption and excretion of sulfapyridine (2-sulfanilyl aminopyridine), Proc. Soc. Exper. Biol. and Med., 1938, xxxix, 486. CrossrefGoogle Scholar22. LONGWOOD PHWB: Observations upon the experimental and clinical use of sulfapyridine. II. The treatment of pneumococcal pneumonia with sulfapyridine, ANN. INT. MED., 1939, xiii, 487. Google Scholar23. LONGBLISS PHEA: The clinical and experimental use of sulfanilamide, sulfapyridine, and allied compounds, 1939, The Macmillan Co., New York. Google Scholar24. MARSHALL EK: Bacterial chemotherapy. The pharmacology of sulfanilamide, Physiol. Rev., 1939, xix, 240. CrossrefGoogle Scholar25. BROWNTHORNTONWILSON WHWBJS: Observations on the absorption, distribution, and excretion of sulfapyridine, Dagenan, or M & B 693, Jr. Clin. Invest., 1939, xviii, 803. CrossrefGoogle Scholar26. LONGHAVILANDEDWARDS PHJWLB: Acute toxicity, absorption, and excretion of sulfathiazole and certain of its derivatives, Proc. Soc. Exper. Biol. and Med., 1940, xliii, 328. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication November 20, 1941.From The New York Hospital and the Departments of Medicine and Pharmacology, Cornell University Medical College.Directed by the Committee on Chemotherapy, Cornell University Medical College, composed of Dr. William DeWitt Andrus, Dr. McKeen Cattell, Dr. Russell L. Cecil, Dr. Vincent du Vigneaud, Dr. Claude E. Forkner, Chairman, Dr. Frank Glenn, and Dr. Norman Plummer.The drugs used in this investigation were supplied by the Lederle Laboratories, Inc. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byModulation of biopharmaceutical properties of acidic drugs using cationic counterions: A critical analysis of FDA-approved pharmaceutical saltsSulfadiazine-Associated Nephrotoxicity in Patients with the Acquired Immunodeficiency SyndromeRenal Complications of Sulfonamide TherapyIncidence of reactions to sulfonamide drugs in infants and childrenSubcutaneous administration of sodium sulfadiazine 1 February 1942Volume 16, Issue 2Page: 269-285KeywordsAdverse reactionsDrug absorptionDrugsExcretionHospital medicinePharmacologySaltsSodiumSulfonamideToxicity ePublished: 1 December 2008 Issue Published: 1 February 1942 PDF downloadLoading ...